Berkeley, CANCT07166406Now EnrollingIRB Ready

Advanced Hepatocellular Carcinoma Clinical Trial in Berkeley, CA

Access cutting-edge advanced hepatocellular carcinoma treatment through this clinical trial at a research site in Berkeley. Study-provided care at no cost to qualified participants.

Sponsored by NRG Oncology

Quick Self-Assessment

See if you qualify for this Berkeley location

Preparing your pre-screening questions…

Expert Care in Berkeley

Access advanced hepatocellular carcinoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related advanced hepatocellular carcinoma treatment provided free

Apply for This Berkeley Location

Check if you qualify for this advanced hepatocellular carcinoma clinical trial in Berkeley, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Berkeley

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Berkeley site if eligible
  4. 4Begin participation

About This Advanced Hepatocellular Carcinoma Study in Berkeley

This phase III trial compares the effect of immunotherapy (IO) with stereotactic body radiation therapy (SBRT) to IO alone in treating patients with liver cancer (hepatocellular cancer) that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). The usual approach is treatment with IO-based drug combinations, such as atezolizumab and bevacizumab, durvalumab and tremelimumab, or ipilimumab and nivolumab. IO with monoclonal antibodies, such as durvalumab, tremelimumab, atezolizumab, nivolumab and ipilimumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor cells. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. SBRT is a type of external radiation therapy that uses special equipment to position a patient and precisely deliver radiation to tumors in the body (except the brain). The total dose of radiation is divided into smaller doses given over several days. This type of radiation therapy helps spare normal tissue. Giving IO with SBRT may be more effective than IO alone in helping patients with advanced hepatocellular cancer live longer.

Sponsor: NRG Oncology

Who Can Participate

Inclusion Criteria

PRIOR TO STEP 1 REGISTRATION:
Diagnosis of hepatocellular carcinoma (HCC) by at least 1 criterion listed below:
Pathologically (histologically or cytologically) proven diagnosis of HCC (strongly recommended)
Radiographically proven (American Association for the Study of Liver Diseases \[AASLD\] criteria) diagnosis of HCC by multiphasic MRI and/or CT scan is allowed.
For patients with a prior or concurrent malignancy, pathologic confirmation of hepatocellular cancer is required.
HCC macrovascular invasion, defined as enhancing vascular thrombosis demonstrating arterial enhancement and venous or delayed venous washout on multiphasic MRI and/or CT is required.
Presence of extrahepatic metastatic disease on CT chest and CT or MRI pelvis, or PET/CT chest/abdomen/pelvis is permitted.
5 or fewer discrete intrahepatic parenchymal foci of HCC.
Total maximal sum of hepatocellular carcinoma tumors, as a single conglomerate, multiple lesions, or infiltrative HCC \< 20 cm in total summed diameter.
No direct primary tumor extension into the stomach, duodenum, small bowel, or large bowel.
No known fibrolamellar HCC, sarcomatoid HCC, or biphenotypic HCC.
Child-Pugh class A or B7 liver function.
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
Not pregnant and not nursing
Negative urine or serum pregnancy test (in persons of childbearing potential) within 30 days prior to registration. Childbearing potential is defined as any person who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal.
Absolute neutrophil count (ANC) ≥ 1,500 cells/mm\^3.
Platelets ≥ 60,000 cells/mm\^3.
Hemoglobin ≥ 8g/dl (Note: The use of transfusion or other intervention to achieve hemoglobin \[Hgb\] ≥ 8g/dl is acceptable).
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 6 x institutional upper limit of normal (ULN).
Total bilirubin \< 4 x institutional ULN.
Creatinine clearance (CrCL) ≥ 30 mL/min/1.73 m\^2 by the Cockcroft-Gault formula.
For treatment of HCC:
Prior surgical resection, transarterial chemoembolization (TACE), and ablation are permitted.
No prior systemic therapy or transarterial radioembolization (TARE) for HCC.
No history of liver transplantation.
For prior treatment for any malignancy:
Prior systemic therapy for a different cancer is allowable, except for prior immunotherapy.
No prior radiotherapy to the region of the study cancer that would result in significant overlap of radiation therapy fields that would lead to excessive cumulative toxicity at the discretion of the investigator.
No medical contraindication to the standard of care immunotherapy.
For patients to be treated with atezolizumab/bevacizumab:
No history of a gastrointestinal (GI) bleed or other clinically significant bleeding event within 6 months prior to study registration.
Systemic immunostimulatory agents (including, but not limited to, interferons and interleukin-2 \[IL-2\]) are prohibited within 4 weeks or five drug elimination half-lives (whichever is longer) prior to registration and during the study period.
No history of allergic reaction to the systemic therapy agent(s), compounds of similar chemical or biologic composition to the systemic therapy agent(s) (or any of its excipients).
PRIOR TO STEP 2 RANDOMIZATION:
Obtain confirmation of payment coverage (insurance or other) for both possible treatment arms.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Berkeley?

Yes, this clinical trial (NCT07166406) has an active research site in Berkeley, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Advanced Hepatocellular Carcinoma Treatment Options in Berkeley, CA

If you're searching for advanced hepatocellular carcinoma treatment options in Berkeley, CA, this clinical trial (NCT07166406) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Berkeley research site is actively enrolling participants for this clinical trial. You'll receive care from experienced advanced hepatocellular carcinoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all advanced hepatocellular carcinoma clinical trials near you to find additional studies recruiting in your area.

More Liver Cancer Trials in Berkeley, CA

See all liver cancer clinical trials recruiting in Berkeley — not just this study.

Browse Liver Cancer Trials in Berkeley →

Browse More Trials by Condition

Liver Cancer TrialsAlzheimers Disease TrialsAtopic Dermatitis TrialsErectile Dysfunction TrialsAll Conditions →

Ready to Join in Berkeley?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Berkeley, CA